(Total Views: 574)
Posted On: 01/31/2023 12:19:40 AM
Post# of 148892
Fair enough. Unintentionally labeled purposeful naysayer.
The answers to your questions in order, are…
Nope.
Not allowed
Covid related. Get vaxxed
Oh yeah, everyone in Brazil got vaxxed
(Side note - the virus got less virulent)
Oops, I forgot, whois Alzheimer
Who knows?
Livimmune makes sense in HIV bc we do more than immune.
Now we finally arrive my desired discussion. When you say this…
“ Wondering about the paper that was going to be published about the oral longer lasting HIV dosage.”
Do you mean the en vitro AAV delivered Leronlimab that Jonah Sacha described in the 12/07/22 CC? Because I don’t think a paper is forthcoming but it was glorious news. And if not, can you be more clear in asking the question. Which paper are you implying hasn’t happened yet and when weee you expecting it?
This one is easy…even I know the answer.
“Let's not forget to mention the "partial hold" on leronlimab by the FDA since mid 2022.”
The partial hold will be lifted by mid 2023 in Cytodyn years.
Any tiger questions?
The answers to your questions in order, are…
Nope.
Not allowed
Covid related. Get vaxxed
Oh yeah, everyone in Brazil got vaxxed
(Side note - the virus got less virulent)
Oops, I forgot, whois Alzheimer
Who knows?
Livimmune makes sense in HIV bc we do more than immune.
Now we finally arrive my desired discussion. When you say this…
“ Wondering about the paper that was going to be published about the oral longer lasting HIV dosage.”
Do you mean the en vitro AAV delivered Leronlimab that Jonah Sacha described in the 12/07/22 CC? Because I don’t think a paper is forthcoming but it was glorious news. And if not, can you be more clear in asking the question. Which paper are you implying hasn’t happened yet and when weee you expecting it?
This one is easy…even I know the answer.
“Let's not forget to mention the "partial hold" on leronlimab by the FDA since mid 2022.”
The partial hold will be lifted by mid 2023 in Cytodyn years.
Any tiger questions?
(0)
(0)Scroll down for more posts ▼
